Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative m... Amarantus Bioscience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. AMBS acquired the rights to the Engineered Skin Substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by AMBS' wholly-owned subsidiary Cutanogen Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor ("MANF"). MANF Therapeutics, Inc. is developing MANF-based products as treatments for brain and ophthalmic disorders. MANF was discovered by the Company's Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS' proprietary discovery engine PhenoGuard. AMBS sold subsidiary Breakthrough Diagnostics to Todos Medical Ltd. in July of 2020. The Company also owns 51% of hemp/CBD company Hempori. Show more
Full US use of ANDiS 350 extraction systems would increase US daily testing capacity by 25% 3D Med extraction capacity increased by 1,000,000 kits per week Extraction reagent and automation...
Amarantus Acquires Majority Interest in CBD Wellness Company Hempori Strong customer retention at both stores in Dallas, TX with growing online presence Focus...
Amarantus Provides 2019 Roadmap New York, NY -- January 7, 2019 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the...
Coeptis Pharma Enters into Agreement to Acquire Elto Pharma New York, NY and Wexford, PA -- November 28, 2018 -- InvestorsHub NewsWire -- Coeptis...
Amarantus Provides Corporate Update New York, NY -- July 20, 2018 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the...
MANF Therapeutics Announces Positive MANF Pre-Clinical Data in Alpha-Synuclein Model of Parkinson's Disease Published in Peer-Reviewed Journal Experimental...
MANF Therapeutics Announces Independent Publication of Positive Data for MANF in Traumatic Brain Injury Animal Model New York, NY -- June 11, 2018 -- InvestorsHub NewsWire...
Amarantus Provides Update on Elto Pharma Capital Formation Plan New York, NY -- June 07, 2018 -- InvestorsHub NewsWire -- Amarantus Bioscience Holdings, Inc...
MANF Therapeutics Announces Publication of Positive Data for MANF in Stroke Animal Model in AAAS Journal Science Advances New York, NY USA -- June 05, 2018...
Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0" Scope of exercised Exclusive Option Agreement...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0001 | -50 | 0.0002 | 0.0002 | 0.0001 | 463 | 0.00014417 | CS |
4 | 0 | 0 | 0.0001 | 0.00055 | 0.0001 | 67808 | 0.00023691 | CS |
12 | 9.9E-5 | 9900 | 1.0E-6 | 0.0401 | 1.0E-6 | 110919 | 0.00016406 | CS |
26 | 0 | 0 | 0.0001 | 0.0401 | 1.0E-6 | 78860 | 0.00015066 | CS |
52 | -0.00055 | -84.6153846154 | 0.00065 | 0.0401 | 1.0E-6 | 725702 | 0.00093364 | CS |
156 | -0.0069 | -98.5714285714 | 0.007 | 0.0401 | 1.0E-6 | 1688560 | 0.00372588 | CS |
260 | -0.0139 | -99.2857142857 | 0.014 | 0.0401 | 1.0E-6 | 1437947 | 0.00597001 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales